<DOC>
	<DOCNO>NCT00332189</DOCNO>
	<brief_summary>The objective study evaluate safety long-term treatment Phenoptin subject phenylketonuria ( PKU ) participate Phase 3 clinical study Phenoptin .</brief_summary>
	<brief_title>Study Phenoptin Subjects With Phenylketonuria Who Participated Protocols PKU-004 PKU-006</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Participation study PKU004 PKU006 Willing able provide write , sign informed consent , case subject age 18 year , provide write assent ( require ) write informed consent parent legal guardian , nature study explain , prior researchrelated procedure Negative urine pregnancy test screening ( female childbearing potential ) Willing able comply study procedure Nonresponsive prior treatment Phenoptin base participation PKU004 PKU006 Perceived unreliable unavailable study participation , age 18 year , parent legal guardian perceive unreliable unavailable Terminated early PKU004 PKU006 , except subject PKU004 roll PKU008 Week 22 , subject PKU006 roll PKU008 Week 10 , subject PKU006 terminate due elevate Phe level follow dietary Phe increase Use investigational product Phenoptin within 30 day prior screen , anticipated requirement investigational agent prior completion schedule study assessment Positive urine pregnancy test screening ( nonsterile female childbearing potential ) , already know pregnant breastfeeding planning pregnancy self partner study Female subject childbearing potential must use effective method birth control , determine PI , willing continue use acceptable birth control measure Concurrent disease condition would interfere study participation safety ( e.g. , seizure disorder , oral steroiddependent asthma condition require oral parenteral corticosteroid administration , insulindependent diabetes ) Any condition , view PI , render subject high risk treatment compliance and/or complete study ALT &gt; 2 time upper limit normal ( i.e. , Grade 1 high base World Health Organization Toxicity Criteria ) screening ( see Appendix 2 ) Serious neuropsychiatric illness ( e.g. , major depression ) currently medical control Prior history organ transplantation Requirement concomitant treatment drug know inhibit folate synthesis ( e.g. , methotrexate ) Concurrent use levodopa Clinical diagnosis primary BH4 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>PKU</keyword>
</DOC>